Medical Tech Firm BioNexus Gene Lab Announces New Ethereum-Focused Treasury Strategy

Adoption Ethereum

Author

Sujha Sundararajan

Author

Sujha Sundararajan

About Author

Sujha has been recognised as 🟣 Women In Crypto 2024 🟣 by BeInCrypto for her leadership in crypto journalism.

Author Profile

Share

Copied

Last updated: 

March 5, 2025

Why Trust Cryptonews

Cryptonews has covered the cryptocurrency industry topics since 2017, aiming to provide informative insights to our readers. Our journalists and analysts have extensive experience in market analysis and blockchain technologies. We strive to maintain high editorial standards, focusing on factual accuracy and balanced reporting across all areas - from cryptocurrencies and blockchain projects to industry events, products, and technological developments. Our ongoing presence in the industry reflects our commitment to delivering relevant information in the evolving world of digital assets. Read more about Cryptonews

Healthcare technology company BioNexus Gene Lab has formally approved Ethereum (ETH) as its primary treasury asset, a Wednesday announcement read. The move marks a strategic shift in the company’s treasury management, making it the first Nasdaq-listed company to include ETH.

The company said that its board of directors has officially approved the ETH-focused treasury strategy. Further, BioNexus Gene Lab released its ETH Strategy Whitepaper, outlining the rationale behind this innovative approach.

Ethereum’s high liquidity, utility and stability compared to other digital assets, has come to the fore, said CEO Sam Tan.

“By integrating Ethereum into our corporate treasury, BioNexus Gene Lab Corp. is embracing the future of financial infrastructure.”

The Ethereum Treasury Strategy Whitepaper

BioNexus’s Ethereum Strategy Whitepaper, which is now available to the public, provides several insights. Some of it includes how crypto integration can facilitate reduced transaction costs, staking capabilities, and enhance investment returns.

The move is a significant trend in the biotechnology sector, where companies are increasingly looking to integrate cryptos as a method of retaining more liquidity.

The Whitepaper also highlights Ethereum’s role in stablecoin settlements and decentralized finance (DeFi), as well as its potential as a long-term corporate treasury asset.

Pro-Crypto Wyoming Shapes Bionexus’ Blockchain Venture

Besides the ETH treasury strategy, the company benefits from the state of Wyoming’s progressive blockchain laws. Bionexus is one of the few publicly-listed companies in the state.

The ‘Cowboy State’ has been attracting business from companies interested in blockchain, with its legal framework for digital asset custody and corporate governance.

Recently, the state announced the launch of a fully backed and compliant stablecoin as a stepping stone toward integrating blockchain into state financial operations, including the State Treasurer’s Office.

Further, the approval of the Wyoming Stable Token Act, offers a supportive environment for blockchain innovation.

“Wyoming’s regulatory leadership further validates our decision, as it fosters an environment where blockchain businesses can thrive,” CEO Tan noted.